Correction to: Clinical Drug Investigation (2019) 39:805–819 10.1007/s40261-019-00826-0
The original version of this article unfortunately contained some mistakes. The corrected details are provided below:
Page 806, column 1, line 3: The text, which previously read:
‘as and’
should read:
‘as’
Page 809, Table 2, column 6, row 29: the cell, which was previously blank, should read:
‘NR’
Page 811, column 1, paragraph 2, sentence 4: The two sets of bracketed text, which previously read:
‘(once-weekly dulaglutide, liraglutide and exenatide ER)’ and ‘(twice-daily exenatide and lixisenatide)’
should read:
‘(once-daily liraglutide, once-weekly dulaglutide and once-weekly exenatide ER)’ and ‘(twice-daily exenatide and once-daily lixisenatide)’
Page 812, Table 3, column 3 and Page 814, Table 4, column 5: The column headings, which previously read:
‘Exenatide 20 mg/wk’
Should read:
‘Exenatide 2 mg/wk’
Page 814, Table 4, column 4: The heading, which previously read:
‘Dulaglutide 0.5/1.0 mg/wk’
Should read:
‘Dulaglutide 1.5 mg/wk’
Page 814, Table 4, column 5, row 7: The 95% CI, which previously read:
‘(83–1.00)’
Should read:
‘(0.83–1.00)’
Page 815, Table 5, footnote ‘b’, which previously read:
Exenatide IR and liraglutide are short-acting; lixisenatide, dulaglutide, exenatide ER and semaglutide are long-acting
Should read:
Exenatide IR and lixisenatide are short-acting; dulaglutide, exenatide ER, liraglutide and semaglutide are long-acting.